Shares of Biolase BIOL rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 68.42% year over year to ($0.06), which missed the estimate of ($0.05).
Revenue of $8,116,000 rose by 69.68% from the same period last year, which beat the estimate of $7,790,000.
Looking Ahead
Biolase hasn't issued any earnings guidance for the time being.
Q2 revenue expected to be between $7,500,000 and $8,500,000.
How To Listen To The Conference Call
Date: May 13, 2021
Time: 04:30 PM
ET Webcast URL: https://ir.biolase.com/news-events/ir-calendar/detail/5569/q1-2021-financial-results-conference-call
Technicals
52-week high: $1.51
52-week low: $0.24
Price action over last quarter: down 31.49%
Company Overview
Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.